Regulatory News
Thursday, May 19, 2016
Roche breast cancer drug Perjeta rejected by UK cost agency
LONDON, May 20 (Reuters) - Roche's breast cancer
drug Perjeta, or pertuzumab, has been turned down for use on
Britain's state health service, making it the latest in a number
of pricey new cancer...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment